文献速递糖尿病

血清和尿液生物标志物组合与尿白蛋白/肌酐比值在预测1型糖尿病肾功能下降中的比较

Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes.
PubMed 文献 · Diabetologia · 2020-01-08

在苏格兰1型糖尿病生物资源库中抽样1629例、中位随访5.1年,评估血清和尿液候选生物标志物能否在基线eGFR之外改善对肾病进展的预测。简约血清生物标志物组合在预测终末eGFR和进展至<30 ml min-1 [1.73 m]-2方面可能优于尿白蛋白/肌酐比值(ACR),其他尿液生物标志物未优于ACR。

要点

  • 7种血清和7种尿液生物标志物与终末eGFR或进展至<30 ml min-1 [1.73 m]-2强相关(均p<2.3×10-3)。
  • 4种血清生物标志物对两项结局的关联独立于ACR,且在正常白蛋白尿参与者中仍有显著关联。
  • 血清生物标志物组合预测终末eGFR的r2从0.702升至0.743,ACR单独升至0.721。

核心结论

  • 简约血清生物标志物组合与血清肌酐一起易于测量,在预测1型糖尿病肾病进展方面可能优于ACR,可能免去尿液检测的需要。

研究设计与样本

  • 从人群代表性的苏格兰糖尿病研究网络1型生物资源库(SDRNT1BIO)中,对起始eGFR低于75 ml min-1 [1.73 m]-2者抽样50%、高于75 ml min-1 [1.73 m]-2者抽样25%,共1629例,中位随访5.1年。
  • 使用多重ELISA和单分子阵列技术测量基于既往大型发现和候选研究的9种血清生物标志物和13种尿液生物标志物。
  • 采用线性回归和逻辑回归模型检验生物标志物与终末eGFR及进展至<30 ml min-1 [1.73 m]-2的关联,均校正基线eGFR;使用惩罚贝叶斯方法识别简约生物标志物组合,通过十折交叉验证评估性能,并与尿ACR及其他临床记录数据比较。

主要发现

  • 校正基线eGFR和其他协变量后,7种血清和7种尿液生物标志物与终末eGFR或进展至<30 ml min-1 [1.73 m]-2强相关(均p<2.3×10-3)。
  • 其中4种血清生物标志物对两项结局的关联独立于ACR。
  • 与终末eGFR和进展至<30 ml min-1 [1.73 m]-2关联最强的血清生物标志物为TNF受体1、肾损伤分子1、CD27抗原、α-1-微球蛋白和多配体蛋白聚糖-1。
  • 这些血清关联在正常白蛋白尿参与者中对两项结局也显著。
  • 在基线协变量基础上,预测终末eGFR的r2从0.702升至0.743(血清生物标志物),ACR单独从0.702升至0.721。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We examined whether candidate biomarkers in serum or urine can improve the prediction of renal disease progression in type 1 diabetes beyond prior eGFR, comparing their performance with urinary albumin/creatinine ratio (ACR). METHODS: From the population-representative Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) we sampled 50% and 25% of those with starting eGFR below and above 75 ml min-1 [1.73 m]-2, respectively (N = 1629), and with median 5.1 years of follow-up. Multiplexed ELISAs and single molecule array technology were used to measure nine serum biomarkers and 13 urine biomarkers based on our and others' prior work using large discovery and candidate studies. Associations with final eGFR and with progression to <30 ml min-1 [1.73] m-2, both adjusted for baseline eGFR, were tested using linear and logistic regression models. Parsimonious biomarker panels were identified using a penalised Bayesian approach, and their performance was evaluated through tenfold cross-validation and compared with using urinary ACR and other clinical record data. RESULTS: Seven serum and seven urine biomarkers were strongly associated with either final eGFR or progression to <30 ml min-1 [1.73 m]-2, adjusting for baseline eGFR and other covariates (all at p<2.3 × 10-3). Of these, associations of four serum biomarkers were independent of ACR for both outcomes. The strongest associations with both final eGFR and progression to <30 ml min-1 [1.73 m]-2 were for serum TNF receptor 1, kidney injury molecule 1, CD27 antigen, α-1-microglobulin and syndecan-1. These serum associations were also significant in normoalbuminuric participants for both outcomes. On top of baseline covariates, the r2 for prediction of final eGFR increased from 0.702 to 0.743 for serum biomarkers, and from 0.702 to 0.721 for ACR alone. The area under the receiver operating characteristic curve for progression to <30 ml min-1 [1.73 m]-2 increased from 0.876 to 0.953 for serum biomarkers, and to 0.911 for ACR alone. Other urinary biomarkers did not outperform ACR. CONCLUSIONS/INTERPRETATION: A parsimonious panel of serum biomarkers easily measurable along with serum creatinine may outperform ACR for predicting renal disease progression in type 1 diabetes, potentially obviating the need for urine testing.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Colombo M, McGurnaghan SJ, Blackbourn LAK, et al. Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia. 2020. PMID: 31915892. doi:10.1007/s00125-019-05081-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。